Jonathan F Tait
Overview
Explore the profile of Jonathan F Tait including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
3287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Byers H, Jacobson A, McFaddin A, Ussakli C, Newlin A, Stanich P, et al.
JCO Precis Oncol
. 2020 Sep;
2.
PMID: 32913991
No abstract available.
2.
Cohen S, Turner E, Beightol M, Jacobson A, Gooley T, Salipante S, et al.
Gastroenterology
. 2016 Jun;
151(3):440-447.e1.
PMID: 27302833
Background & Aims: Some colorectal and endometrial tumors with microsatellite instability not attributable to MLH1 hypermethylation or germline mutations contain 2 or more somatic mutations in genes encoding mismatch repair...
3.
Shirts B, Casadei S, Jacobson A, Lee M, Gulsuner S, Bennett R, et al.
Genet Med
. 2016 Feb;
18(10):974-81.
PMID: 26845104
Purpose: Screening multiple genes for inherited cancer predisposition expands opportunities for cancer prevention; however, reports of variants of uncertain significance (VUS) may limit clinical usefulness. We used an expert-driven approach,...
4.
Austin M, Smith C, Pritchard C, Tait J
Arch Pathol Lab Med
. 2015 Jun;
140(2):130-3.
PMID: 26098132
Context: Complex molecular assays are increasingly used to direct therapy and provide diagnostic and prognostic information but can require relatively large amounts of DNA. Objectives: To provide data to pathologists...
5.
Pritchard C, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, et al.
Nat Commun
. 2014 Sep;
5:4988.
PMID: 25255306
A hypermutated subtype of advanced prostate cancer was recently described, but prevalence and mechanisms have not been well-characterized. Here we find that 12% (7 of 60) of advanced prostate cancers...
6.
Pritchard C, Salipante S, Koehler K, Smith C, Scroggins S, Wood B, et al.
J Mol Diagn
. 2013 Nov;
16(1):56-67.
PMID: 24189654
Recent years have seen development and implementation of anticancer therapies targeted to particular gene mutations, but methods to assay clinical cancer specimens in a comprehensive way for the critical mutations...
7.
Cheng H, Yi H, Kim Y, Kroh E, Chien J, Eaton K, et al.
PLoS One
. 2013 Jun;
8(6):e64795.
PMID: 23762257
Circulating, cell-free microRNAs (miRNAs) are promising candidate biomarkers, but optimal conditions for processing blood specimens for miRNA measurement remain to be established. Our previous work showed that the majority of...
8.
Pritchard C, Smith C, Salipante S, Lee M, Thornton A, Nord A, et al.
J Mol Diagn
. 2012 Jun;
14(4):357-66.
PMID: 22658618
Lynch syndrome (hereditary nonpolyposis colon cancer) and adenomatous polyposis syndromes frequently have overlapping clinical features. Current approaches for molecular genetic testing are often stepwise, taking a best-candidate gene approach with...
9.
Pritchard C, Kroh E, Wood B, Arroyo J, Dougherty K, Miyaji M, et al.
Cancer Prev Res (Phila)
. 2011 Dec;
5(3):492-497.
PMID: 22158052
Circulating, cell-free microRNAs (miRNAs) hold great promise as a new class of cancer biomarkers due to their surprisingly high stability in plasma, association with disease states, and ease of sensitive...
10.
Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D, et al.
Proc Natl Acad Sci U S A
. 2011 Mar;
108(12):5003-8.
PMID: 21383194
MicroRNAs (miRNAs) circulate in the bloodstream in a highly stable, extracellular form and are being developed as blood-based biomarkers for cancer and other diseases. However, the mechanism underlying their remarkable...